Skip to content

Erasca, Inc. ERAS Enterprise value

Enterprise value at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$158.92B-2.6%
Eli Lilly logo
Eli LillyLLY
$859.77B+10.6%
Pfizer logo
PfizerPFE
$222.4B+9.2%
Amgen logo
AmgenAMGN
$246.43B+9.9%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$18.99B+198%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$2.86B+2,204%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.25B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s enterprise value?
Erasca, Inc. (ERAS) reported enterprise value of $5.03B in Q1 2026.
How has Erasca, Inc.'s enterprise value changed year-over-year?
Erasca, Inc.'s enterprise value increased by 1264.7% year-over-year, from $368.4M to $5.03B.
What is the long-term trend for Erasca, Inc.'s enterprise value?
Over 4 years (2021 to 2025), Erasca, Inc.'s enterprise value has grown at a -20.6% compound annual growth rate (CAGR), from $2.59B to $1.03B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.